HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing […]
Rigetti Computing Wins Innovate UK Competition to Deliver a 24-qubit Quantum Computing System to the National Quantum Computing Centre
LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) — Rigetti UK Limited, a wholly owned subsidiary of Rigetti Computing, Inc. (Nasdaq: RGTI) […]
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate […]
TSX News -
illumin Announces Personnel Changes
TORONTO, Feb. 05, 2024 (GLOBE NEWSWIRE) — illumin Holdings Inc. (TSX:ILLM) (“illumin” or the “Company”) announced that effective today, Mr. […]
Kforce Reports Fourth Quarter 2023 Revenue of $363.4 Million and Earnings Per Share of $0.82; Full Year 2023 EPS of $3.13 Per Share, as Reported, and $3.49 Per Share, as Adjusted; Board of Directors Approves 5.5% Increase in Dividend and Increases Share Buyback Authorization to $100 Million
TAMPA, Fla., Feb. 05, 2024 (GLOBE NEWSWIRE) — Kforce Inc. (Nasdaq: KFRC), a solutions firm that specializes in technology and […]
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
WALTHAM, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect […]
Alico, Inc. to Announce First Quarter 2024 Financial Results on Wednesday, February 7, 2024
FORT MYERS, Fla., Feb. 05, 2024 (GLOBE NEWSWIRE) — Alico, Inc. (“Alico” or the “Company”) (Nasdaq: ALCO) today announced that […]
Symbotic Reports First Quarter Fiscal Year 2024 Results
WILMINGTON, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) — Symbotic Inc. (Nasdaq: SYM), a leader in A.I.-enabled robotics technology for the […]
TSX News -
Coveo Reports Third Quarter Fiscal 2024 Financial Results
SaaS Subscription Revenue(1)of $29.9 million, ahead of previous guidanceOperating loss reduced by 40% year-over-year; Adjusted Operating Loss(2)well ahead of guidanceContinued […]
TSX News -
James Mannebach is appointed as CEO of Velan
MONTREAL, Feb. 05, 2024 (GLOBE NEWSWIRE) — Velan Inc. (“Velan”) (TSX: VLN) today announces that its board of directors has […]
